Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRE with Chemotherapy for Advanced Pancreatic Cancer
NCT03484299Phase 1Recruiting
- Sponsor
- University of Louisville
- Start
- May 2018
- Primary completion
- Jul 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine and FOLFIRINOX in pancreatic adenocarcinoma (PDAC), sponsored by University of Louisville. Primary endpoint: Incidence of Adverse and Serious Adverse events. Started May 2018; status: recruiting.
02
Drugs
gemcitabineFOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03484299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03484299.